Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4572 Steroid dosing to prevent tumour flare reaction with 177Lu-DOTATATE

Introduction: Tumour flare reactions including increased pain and small bowel obstruction (SBO) have been reported in patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) receiving 177Lu-DOTATATE. Retrospective reviews report tumour flare reactions in 6 to 40 percent of high-risk patients receiving 177Lu-DOTATATE and report success with using corticosteroid prophylaxis to prevent tumour flare recurrence with subsequent doses of 177Lu-DOTATATE (Strosberg, et al., 2021; Salner, et al., 2020).

Conference:

Presenting Author:

Authors: Cass A, Skotte E, Wheless M, Stockton S, Ramirez R,

Keywords: 177Lu-DOTATATE, corticosteroid prophylaxis, tumour flare,

#4345 Real-life results of the treatment with lutetium in advanced neuroendocrine tumours

Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.

Conference:

Presenting Author: Campos Ramírez S

Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,

Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,

#627 Pancreatic Neuroendocrine Tumors: Two Different TNM Staging Systems

Introduction: Several staging systems for pancreatic neuroendocrine tumors (PNETs) exist but the most appropriate one has not been defined.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Martin-Perez E, Gomez-Ramirez J, Garcia-Sanz I, Posada M, Di Martino M,

Keywords: pancreatic neuroendocrine tumors, TNM staging, survival,